Sanofi Shares Rise 1.78% Boosted by Strategic FDA Designation
Sanofi shares increased by 1.78% this Tuesday morning, February 10, reaching 81.72 euros. This rebound follows the announcement of a major designation granted by the U.S. Food and Drug Administration. However, the French pharmaceutical company's stock has shown mixed performance over the past year.
Investor Interest Rekindled by Regulatory Recognition
The renewed investor interest is notably due to a dual regulatory recognition received by Sanofi for its treatment rilzabrutinib, marketed under the name Wayrilz. The FDA has granted the drug the designation of a breakthrough therapy for warm autoimmune hemolytic anemia, a rare condition affecting red blood cells. This distinction, reserved for therapies meeting an unmet medical need, could significantly accelerate the regulatory approval process in the United States. Concurrently, Japan has granted rilzabrutinib orphan drug status for the same therapeutic indication. These recognitions obtained on February 9 are based on clinical data still under evaluation. Nevertheless, they demonstrate the commercial potential of the drug candidate in a segment of rare diseases where therapeutic options remain limited. For the French laboratory, this progress in its immunology portfolio could contribute to diversifying its future revenue sources.
Technical Perspective on the Stock's Rebound
From a technical standpoint, the observed rebound occurs in a still fragile market context for the pharmaceutical giant. The price remains slightly below its 50-session moving average established at 82.01 euros, and more significantly behind its 200-day moving average set at 84.67 euros. This configuration highlights the downward trend observed in recent months, with a drop of 20.94% over twelve months. The stock is now fluctuating between a support identified at 77.08 euros and a resistance placed at 84.44 euros. The RSI is positioned at 55, indicating a neutral zone without signs of overheating or overselling. The MACD histogram shows a rebound with a value of 0.27, suggesting an attempt at a short-term turnaround after several weeks of selling pressure. The one-month volatility stands at 7.31, reflecting still nervous movements on the stock. These elements translate into a phase of hesitation for the stock, which will need to sustainably break through its resistance to begin a true recovery.
